Corona Virus 2019-2020

[jdaniele]

So this has made national news and we're being overwhelmed with information. Anything worth posting please put in here regarding this subject. CodeBrosForums is mostly about technology but we do allow some other topics within their own subforums.

What is Corona Virus (also known as COVID-19)?:
According to the CDC, COVID-19 is known as a "novel coronavirus." On their website it reads, "A novel coronavirus is a new coronavirus that has not been previously identified. The virus causing coronavirus disease 2019 (COVID-19), is not the same as the coronaviruses that commonly circulate among humans and cause mild illness, like the common cold."
https://www.cdc.gov/coronavirus/2019-ncov/faq.html#basics

This virus is thought to be spread from person-to-person contact. So avoid crowds and make sure to avoid touching places like your face. Washing your hands properly is very important.
https://www.cdc.gov/coronavirus/2019-ncov/prepare/prevention.html

Even though chances of getting bad sick are low (as of this post) it's still good to keep the spreading of this as low as possible.

[jdaniele]

I think Google was gonna do something like this. So far it looks really useful. Nice job Apple!

https://apple.com/covid19

[jdaniele]

Here's some of the data and information Google is providing.

General:
https://www.google.com/covid19/

Find a remote job:
https://www.google.com/search?q=remote+jobs&ibp=htl;jobs&rciv=jb#fpstate=tlexp

Heat Map:
https://www.google.com/covid19-map/

[jdaniele]

Information regrading masks and how effective they are.

https://multimedia.3m.com/mws/media/1791500O/comparison-ffp2-kn95-n95-filtering-facepiece-respirator-classes-tb.pdf

This document is only intended to help clarify some key similarities between such references, specifically to the following FFR
performance standards:
• N95 (United States NIOSH-42CFR84)
• FFP2 (Europe EN 149-2001)
• KN95 (China GB2626-2006)
• P2 (Australia/New Zealand AS/NZA 1716:2012)
• Korea 1st class (Korea KMOEL - 2017-64)
• DS2 (Japan JMHLW-Notification 214, 2018)

https://www.cdc.gov/niosh/npptl/topics/respirators/factsheets/respsars.html

An N-95 respirator is one of nine types of disposable particulate respirators.
Particulate respirators are also known as “air-purifying respirators” because they protect by filtering particles out of the air as you breathe. These respirators protect only against particles—not gases or vapors. Since airborne biological agents such as bacteria or viruses are particles, they can be filtered by particulate respirators.

Respirators that filter out at least 95% of airborne particles during “worse case” testing using a “most-penetrating” sized particle are given a 95 rating. Those that filter out at least 99% receive a “99” rating. And those that filter at least 99.97% (essentially 100%) receive a “100” rating.

Respirators in this family are rated as N, R, or P for protection against oils. This rating is important in industry because some industrial oils can degrade the filter performance so it doesn’t filter properly.* Respirators are rated “N,” if they are Not resistant to oil, “R” if somewhat Resistant to oil, and “P” if strongly resistant (oil Proof). Thus, there are nine types of disposable particulate respirators:

N-95, N-99, and N-100;
R-95, R-99, and R-100;
P-95, P-99, and P-100

https://smartairfilters.com/en/blog/whats-the-difference-between-n95-and-kn95-masks/

In short, N95 masks are the US standards for respirator masks; KN95 masks are the Chinese standards for masks. These are the requirements that the US National Institute for Occupational Safety and Health requires manufacturers to meet in order to label their masks as N95s. Despite the long list of differences, the two masks are equivalent or nearly equivalent on the features that most people care about.

[jdaniele]

Saw this on The Daily Show
https://ncov2019.live
Shows all the data for COVID19 in one place.

Looks like it sources from https://cov19.cc

[jdaniele]

https://www.who.int/emergencies/diseases/novel-coronavirus-2019/interactive-timeline

[jdaniele]

Vaccine Status seems to be alittle harder to get regular information outside of news headlines. I found this website with a list of some familiar ones and where they stand.

https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker

[jdaniele]

Vaccine Status seems to be alittle harder to get regular information outside of news headlines. I found this website with a list of some familiar ones and where they stand.

https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker

So now pFizer says they're vaccine is testing with a 90% effective rate. They're aiming to get an emergency use approval so we might see something at the end of November but it still won't be widely available still until project next year.

https://www.businesswire.com/news/home/20201109005539/en/
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against

“Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19,” said Dr. Albert Bourla, Pfizer Chairman and CEO. “We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen. With today’s news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis. We look forward to sharing additional efficacy and safety data generated from thousands of participants in the coming weeks.”After discussion with the FDA, the companies recently elected to drop the 32-case interim analysis and conduct the first interim analysis at a minimum of 62 cases. Upon the conclusion of those discussions, the evaluable case count reached 94 and the DMC performed its first analysis on all cases. The case split between vaccinated individuals and those who received the placebo indicates a vaccine efficacy rate above 90%, at 7 days after the second dose. This means that protection is achieved 28 days after the initiation of the vaccination, which consists of a 2-dose schedule. As the study continues, the final vaccine efficacy percentage may vary. The DMC has not reported any serious safety concerns and recommends that the study continue to collect additional safety and efficacy data as planned. The data will be discussed with regulatory authorities worldwide.